An Immune Culprit in IBD?

Patients with Crohn’s disease or ulcerative colitis have reduced levels of an important regulator of the immune response—the receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF)—according to a study by Jonathan Goldstein et al. in the July issue of Gastroenterology. The inflammatory bowel diseases (IBD) ulcerative colitis and Crohn’s disease arise from

Read more

Tracking Crohn’s Therapy

Measuring blood levels of C-reactive protein (CRP), a marker of inflammation, is a good way to monitor recovery from Crohn’s disease (CD) in patients being treated with infliximab, according to Matthias Jürgens et al. in the May issue of Clinical Gastroenterology and Hepatology. CRP is a protein released into the blood

Read more

IBD Risk Beyond the Bowel

Venous thromboembolism (VTE) is a recurring problem for patients with inflammatory bowel disease (IBD), according to a clinical study by Gottfried Novacek et al. in this month’s issue of Gastroenterology. People with IBD have a high risk for developing blood clots, but it is not clear if they should receive

Read more

Curbing Crohn’s for the Long Term?

Most people with Crohn’s disease receive surgery, yet the disease comes back a short time later. A study in the July issue of Clinical Gastroenterology and Hepatology reports that giving patients low doses of infliximab immediately after surgery prevents disease recurrence over long time periods. Dario Sorrentino et al. began

Read more